• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Acute Lymphoblastic Leukaemia (ALL) - Articles and news items

b-all

First patient treated in Phase I UCART19 trial in paediatric B-ALL

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL…

INO-VATE ALL

Final results from the INO-VATE ALL study of inotuzumab ozogamicin

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

Results showed improvement over chemotherapy on a number of measures including complete haematologic remission and progression-free survival…

blincyto

Blincyto improves overall survival in B-cell precursor acute lymphoblastic leukaemia

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

Amgen’s Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care…

acute lymphoblastic leukaemia

Two new types of childhood leukaemia discovered

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Using next-generation sequencing technology, researchers were able to study the genome of cancer cells, which is how they discovered the new cancer types…

blincyto

Amgen submits sBLA for Blincyto to the FDA

Industry news / 2 March 2016 / Victoria White

The sBLA includes new data supporting the treatment of paediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)…

blincyto

Phase 3 study of Blincyto in ALL meets primary endpoint

Industry news / 5 February 2016 / Victoria White

Blincyto is a BiTE antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells…

pharmaceutical industry

European Pharmaceutical Review’s top 10 stories from 2015

Blog / 28 January 2016 / Victoria White, Digital Content Producer, European Pharmaceutical Review

2015 was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines…

oncaspar

Marketing Authorisation granted for Oncaspar as combination therapy in ALL

Industry news / 19 January 2016 / Victoria White

With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells…

CTL019

CTL019 demonstrates 93% remission in paediatric patients with r/r ALL

Industry news / 8 December 2015 / Victoria White

This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia…

blincyto

EC approves Blincyto for acute lymphoblastic leukaemia

Industry news / 24 November 2015 / Victoria White

Blincyto is the first bispecific CD19-directed CD3 T cell engager (BiTE) antibody construct approved in European Union…

ucart19

Servier exercises options to acquire worldwide rights to UCART19

Industry news / 19 November 2015 / Victoria White

Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia…

ucart19

UCART19 used to treat ‘incurable’ leukaemia

Industry news / 6 November 2015 / Victoria White

A team at Great Ormond Street Hospital has used UCART 19 cells to treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia with positive results…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +